Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions

Magnetic resonance imaging (MRI) was used to quantify myocardial iron loading by T2* in 11 transfusion‐dependent good prognostic myelodysplastic syndrome (MDS) patients. Myocardial T2*, left ventricular function and hepatic T2* were measured simultaneously. Patients had been on transfusion therapy for 13–123 months and had serum ferritin levels of 1109–6148 μg/l at the time of study. Five patients had not commenced iron chelation and had been transfused with a median of 63 red cell units and had a median serum ferritin level of 1490 μg/l. Six patients were on iron chelation and had been transfused with a median of 112 red cell units and had a median serum ferritin level of 4809 μg/l. Hepatic iron overload was mild in two, moderate in seven and severe in two patients. The median liver iron concentration was 5·9 mg/g dry weight in chelated patients and 9·5 mg/g in non‐chelated patients (P = 0·17; not significant). Myocardial T2* indicated absent iron loading in 10/11 patients (91%; 95% confidence interval 62–98%) and borderline‐normal in one patient. Left ventricular function was normal in all patients. No correlation was observed between increasing serum ferritin levels, hepatic iron overload and myocardial T2*. A long latent period relative to hepatic iron loading appears to predate the development of myocardial iron loading in transfusion‐dependent MDS patients.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  D. Pennell,et al.  Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron , 2007, Journal of magnetic resonance imaging : JMRI.

[3]  Mark A Westwood,et al.  Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.

[4]  D. Pennell,et al.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[5]  D. Pennell,et al.  Calibration of Myocardial T2* Values in Post-Mortem Hearts. , 2005 .

[6]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  David N. Firmin,et al.  Intercentre Reproducibility of Magnetic Resonance T2* Measurements of Myocardial Iron in Thalassaemia , 2005, The International Journal of Cardiovascular Imaging.

[8]  D. Tsiapras,et al.  A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with β‐thalassemia major , 2005, European journal of haematology.

[9]  Thomas D. Coates,et al.  Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.

[10]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[11]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[12]  Mark A Westwood,et al.  Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia , 2003, Journal of magnetic resonance imaging : JMRI.

[13]  D. Pennell,et al.  A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.

[14]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[15]  F. Jensen,et al.  Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. , 2003, Blood.

[16]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[17]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[18]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[19]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[20]  C. Kishan,et al.  Iron overload and the heart. , 2000, The Journal of the Arkansas Medical Society.

[21]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[22]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[23]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[24]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[25]  U. Germing,et al.  [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. , 1992, Beitrage zur Infusionstherapie = Contributions to infusion therapy.

[26]  E. Arbustini,et al.  Myocardial iron grading by endomyocardial biopsy. A clinico‐pathologic study on iron overloaded patients , 1989, European journal of haematology.

[27]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.